Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing […]